CN Patent

CN114605327A — 可用作激酶抑制剂的化合物

Assigned to Loxo Oncology Inc · Expires 2022-06-10 · 4y expired

What this patent protects

本发明涉及可用作激酶抑制剂的新型化合物。本发明的化合物是酪氨酸激酶抑制剂。特别地，本发明的化合物可用作布鲁顿酪氨酸激酶(BTK)的抑制剂。本发明还考虑了这些化合物在治疗可通过抑制布鲁顿酪氨酸激酶而治疗的病症例如癌症、淋巴瘤、白血病和免疫疾病中的用途。

USPTO Abstract

本发明涉及可用作激酶抑制剂的新型化合物。本发明的化合物是酪氨酸激酶抑制剂。特别地，本发明的化合物可用作布鲁顿酪氨酸激酶(BTK)的抑制剂。本发明还考虑了这些化合物在治疗可通过抑制布鲁顿酪氨酸激酶而治疗的病症例如癌症、淋巴瘤、白血病和免疫疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN114605327A
Jurisdiction: CN
Classification: —
Expires: 2022-06-10
Drug substance claim: No
Drug product claim: No
Assignee: Loxo Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.